



**LEGISLATIVE FISCAL OFFICE
Fiscal Note**

Fiscal Note On: **SB 43** SLS 26RS 83
 Bill Text Version: **REENGROSSED**
 Opp. Chamb. Action: **w/ HSE FLOOR AMD**
 Proposed Amd.: **w/ PROP CONF COMM AMD**
 Sub. Bill For.:

Date: May 27, 2026 4:40 PM	Author: MCMATH
Dept./Agy.: LDH - Office of Behavioral Health	Analyst: Anthony Shamis
Subject: Psychedelic-assisted Therapy	

HEALTH SERVICES REF INCREASE GF EX See Note Page 1 of 1
 Provides relative to psychedelic-assisted therapy. (8/1/26)

Proposed law establishes the Psychedelic-Assisted Therapy Initiative within the Louisiana Department of Health (LDH), Office of Behavioral Health (OBH). The purpose of this program shall be: (1) to identify academic health centers conducting clinical studies and clinical trial-enabling studies for use of psychedelic-assisted therapy for the treatment of opioid use disorders, co-occurring substance use disorders, and treatment-resistant neurological or mental health conditions, and (2) to utilize the human service districts and authorities to identify eligible patients to participate in the studies. Proposed law requires academic health centers to coordinate with parishes to utilize opioid settlement funds to enroll eligible patients residing in the parish to participate in the studies. In addition to opioid settlement funds, LDH may seek monies from other sources, including federal funds, gifts, grants, and donations. Proposed law requires each academic health center participating in the program to submit a progress report to LDH, no later than January first of each year. Proposed law requires LDH to prepare a compiled report of data received from academic health centers, and submit the report to the legislature by March first of each year. Proposed law authorizes academic health centers to coordinate with other states that are conducting clinical trials for use of psychedelic-assisted therapy. Proposed law authorizes an academic health center to enter into an agreement with a drug developer to establish a consortium to conduct drug development clinical trials with ibogaine and psychedelic medication/treatments. Proposed law provides for the distribution of revenue attributable to intellectual property rights and other commercial rights arising from drug development clinical trials conducted by a consortium. Effective August 1, 2026.

EXPENDITURES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	INCREASE	INCREASE	INCREASE	INCREASE	INCREASE	
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	\$0
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0

Annual Total

REVENUES	2026-27	2027-28	2028-29	2029-30	2030-31	5 -YEAR TOTAL
State Gen. Fd.	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Agy. Self-Gen.	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Local Funds	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	

Annual Total

EXPENDITURE EXPLANATION

Proposed law is anticipated to increase SGF expenditures within the Louisiana Department of Health (LDH), Office of Behavioral Health (OBH), by an indeterminable but minimal amount associated with additional administrative workload required to maintain records of all academic health centers participating in the Psychedelic-Assisted Therapy Initiative. LDH indicates that this workload can be absorbed using existing staff and resources.

REVENUE EXPLANATION

Proposed law allows parishes to use opioid settlement funds to enroll eligible residents in clinical studies. In addition to opioid settlement funds, LDH may seek and accept voluntary funds from any source, including federal funds, gifts, grants, and donations, to support expenditures related to the Psychedelic-Assisted Therapy Program. It is unclear whether LDH may be able to secure sufficient alternative funding sources to fully offset its reported expenditures.

Proposed law requires that any revenue attributable to intellectual property rights and other commercial rights arising from drug development clinical trials conducted by a consortium pursuant to this measure, during the period for which the trials are funded and any subsequent period of commercialization, be allocated as follows: (1) not less than 2.5% of net sales running royalty to the state (assumed in this fiscal note to be SGF), and (2) the remainder to the members of the consortium in amounts specified by written agreement. Any potential revenues are speculative and cannot be estimated.

Senate Dual Referral Rules
 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}
 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

House
 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}
 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

Alan M. Boxberger
 Alan M. Boxberger
 Legislative Fiscal Officer